Pfizer Inc. $PFE Shares Sold by Wilkins Investment Counsel Inc.

Wilkins Investment Counsel Inc. lessened its position in Pfizer Inc. (NYSE:PFE) by 10.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 179,355 shares of the biopharmaceutical company’s stock after selling 20,005 shares during the period. Wilkins Investment Counsel Inc.’s holdings in Pfizer were worth $4,466,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of PFE. Brighton Jones LLC increased its position in Pfizer by 1,282.4% during the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after purchasing an additional 618,117 shares during the last quarter. Revolve Wealth Partners LLC increased its position in Pfizer by 12.5% during the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock worth $498,000 after purchasing an additional 2,087 shares during the last quarter. United Bank increased its position in Pfizer by 12.4% during the second quarter. United Bank now owns 58,087 shares of the biopharmaceutical company’s stock worth $1,408,000 after purchasing an additional 6,415 shares during the last quarter. Sei Investments Co. increased its position in Pfizer by 31.5% during the second quarter. Sei Investments Co. now owns 2,635,691 shares of the biopharmaceutical company’s stock worth $63,889,000 after purchasing an additional 631,523 shares during the last quarter. Finally, HUB Investment Partners LLC increased its position in Pfizer by 45.3% during the second quarter. HUB Investment Partners LLC now owns 102,327 shares of the biopharmaceutical company’s stock worth $2,480,000 after purchasing an additional 31,896 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently commented on PFE. Bank of America dropped their price target on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a research report on Thursday, April 9th. Morgan Stanley upped their price target on shares of Pfizer from $27.00 to $28.00 and gave the stock an “equal weight” rating in a research report on Friday, April 10th. Argus raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $35.00 price target for the company in a research report on Monday, March 2nd. Cantor Fitzgerald reissued a “neutral” rating and issued a $27.00 price objective on shares of Pfizer in a research report on Wednesday, February 4th. Finally, BMO Capital Markets reissued an “outperform” rating and issued a $30.00 price objective on shares of Pfizer in a research report on Monday, March 9th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, twelve have given a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat.com, Pfizer currently has a consensus rating of “Hold” and an average target price of $28.74.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: FDA approval for a Pfizer–Arvinas breast cancer therapy — The U.S. FDA approved the co‑developed drug for a breast cancer indication, giving Pfizer an additional commercial launch and validating its oncology partnership pipeline. This approval creates a new near‑ and medium‑term revenue opportunity and reduces development risk for the asset. US FDA approves Pfizer, Arvinas’ breast cancer drug
• Positive Sentiment: Vyndamax patent settlements extend exclusivity to 2031 — Pfizer reached settlements with multiple generic filers that effectively push back generic entry for Vyndamax (tafamidis), protecting a meaningful revenue stream and reducing downside risk from near‑term generic competition. That supports cash flow visibility into the next decade. Pfizer Reaches Settlement to Extend VYNDAMAX Patent Protection Until 2031
• Positive Sentiment: Late‑stage win for multiple myeloma drug Elrexfio — Pfizer reported a late‑stage trial success for Elrexfio, which could expand its oncology franchise and add future revenue streams if regulatory filings follow. Clinical wins can meaningfully re‑rate biotech exposure over time. Pfizer posts late-stage trial win for multiple myeloma therapy Elrexfio
• Positive Sentiment: PADCEV supplemental BLA accepted for priority review — Pfizer (with Astellas) secured FDA acceptance of a PADCEV sBLA for a new use, which could expand indications and sales if approved. This is another program that supports medium‑term growth optionality. Pfizer Among Best Medical Stocks Under $30 to Invest In?
• Neutral Sentiment: Q1 earnings and guidance in focus (May 5) — Wall Street is watching first‑quarter results and guidance; Zacks and other outlets highlight consensus estimates and key revenue/margin line items, with traders positioning ahead of potential beats and for commentary on obesity and specialty drug performance. Earnings will likely be the short‑term catalyst for direction. Buy, Sell or Hold Pfizer Stock? Key Tips Ahead of Q1 Earnings
• Negative Sentiment: Analyst caution and price‑target cuts are weighing on sentiment — Goldman reportedly trimmed its target and some sell‑side commentary highlights growth concerns despite the patent wins; Morgan Stanley reiterated Equal Weight and flagged patent/growth uncertainty. That cautious analyst tone can sap momentum and contribute to intraday selling. Pfizer Stock Opinions on Vyndamax Settlements and Earnings Outlook Morgan Stanley Maintains Pfizer at Equal Weight

Pfizer Price Performance

Pfizer stock opened at $26.35 on Friday. Pfizer Inc. has a 52-week low of $21.97 and a 52-week high of $28.75. The firm has a fifty day moving average of $27.17 and a 200-day moving average of $26.10. The firm has a market capitalization of $149.80 billion, a P/E ratio of 19.37 and a beta of 0.35. The company has a quick ratio of 0.87, a current ratio of 1.16 and a debt-to-equity ratio of 0.71.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.57 by $0.09. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The company had revenue of $17.56 billion during the quarter, compared to analyst estimates of $16.93 billion. During the same quarter in the prior year, the business earned $0.63 earnings per share. The business’s quarterly revenue was down 1.2% compared to the same quarter last year. As a group, analysts predict that Pfizer Inc. will post 2.99 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 12th. Stockholders of record on Friday, May 8th will be given a $0.43 dividend. The ex-dividend date of this dividend is Friday, May 8th. This represents a $1.72 annualized dividend and a dividend yield of 6.5%. Pfizer’s dividend payout ratio is presently 126.47%.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.